Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sirna Therapeutics Inc -- Ignore unavailable to you. Want to Upgrade?

To: Scott Ozer who wrote (286)	11/27/1999 9:15:00 AM
From: Thomas	Respond to of 562

Hi Scott, CTT is something like Competitive Technologies Inc. or something. They are an outfit that does patent licensing for universities, and are the actual patent assignee on many of RZYM's patents and CTT has exclusively licensed those patents to RZYM in exchange for a license fee (around 5% of revenues if my memory serves correctly). I found my original diagram of the main patent licensing mechanics for the Cech patents (which is a tangled web indeed), and it goes something like this: University of Colorado ("CU") (Cech)-> CU/ University Research Corp ("URC")-> Competitive Technologies, Inc. ("CTI")-> US Biochemical Corp ("USB")-> RZYM who, as a result, has "exclusive worldwide right to use and sell the RNA patents" Of course you can find all the exact legal descriptions in RZYM's SEC filings, but that is the gist of it. Hope that answers your question. Cheers, Thomas